Table of contents

Key facts

Active substance
Recombinant human IgGlA monoclonal Fab antibody
Therapeutic area
Cardiovascular diseases
Decision number
PIP number
Pharmaceutical form(s)
Solution for infusion
Condition(s) / indication(s)
Reversal of antiplatelet effects of ticagrelor in patients with uncontrolled major or life-threatening bleeding or requiring urgent surgery or invasive procedure
Route(s) of administration
Intravenous use
Contact for public enquiries
PhaseBio Pharmaceuticals Inc.

E-mail: lauren.richardson@phasebio.com
Tel. +1 6109816507

Decision type
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)


How useful was this page?

Add your rating